Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -145.12% is 44% below its 1-year average of -100.91%, near the low end of its 1-year range (-155.82%–0.00%).
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -155.82%.
NET PROFIT MARGIN
-145.12%
NET PROFIT MARGIN AVG TTM
N/A
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 654 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Mobia Medical, Inc. Common Stock
Market Cap
$310.71M
Net Profit Margin
-145.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$307.45M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-6520.67%
5Y Avg
-12425.66%
Market Cap
$320.27M
Net Profit Margin
-214.74%
TTM Avg
-178.01%
3Y Avg
-157.31%
5Y Avg
-157.31%
Market Cap
$323.41M
Net Profit Margin
-289.44%
TTM Avg
-294.02%
3Y Avg
-409.64%
5Y Avg
-336.94%
Market Cap
$293.47M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$293.28M
Net Profit Margin
-103.29%
TTM Avg
-83.69%
3Y Avg
-107.92%
5Y Avg
-85.90%
Market Cap
$292.79M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$330.19M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$331.68M
Net Profit Margin
-81.76%
TTM Avg
-64.66%
3Y Avg
-75.38%
5Y Avg
-73.80%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $310.71M | -145.12% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $307.45M | 0.00% | 0.00% | -6520.67% | -12425.66% |
| CapsoVision, Inc. (CV)vs › | $320.27M | -214.74% | -178.01% | -157.31% | -157.31% |
| C4 Therapeutics, Inc. (CCCC)vs › | $323.41M | -289.44% | -294.02% | -409.64% | -336.94% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.47M | 0.00% | 0.00% | 0.00% | 0.00% |
| Standard BioTools Inc. (LAB)vs › | $293.28M | -103.29% | -83.69% | -107.92% | -85.90% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $292.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cabaletta Bio, Inc. (CABA)vs › | $330.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $331.68M | -81.76% | -64.66% | -75.38% | -73.80% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | -246.42% | 611.54% | -783.13% | -1134.34% |
Operating Margin
-144.7%
Net Profit Margin
-145.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -155.82% |
| 2026-03-31 | -146.93% |
| 2025-12-31 | 0.00% |
